Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Weight Reduction Observations A 2025 network meta-analysis published in the Journal of the Endocrine Society compared data from separate clinical trials: A systematic review examining multiple agents reported: Tirzepatide (15 mg): Up to 17.8% weight reduction from baseline Retatrutide (12 mg): Up to 24.2% weight reduction from baseline Semaglutide (2.4 mg): Up to 14% weight reduction for reference Phase 2 Trial Results: Retatrutide Published in the New England Journal of Medicine, the Phase 2 trial of retatrutide in adults with obesity showed dose-dependent reductions in body weight of up to 24% after 48 weeks of treatment
BROWSE OUR RESEARCH PRODUCTS Showing all 55 results Sale
If you are interested in retatrutide or other emerging weight management treatments, the most appropriate first step is to speak openly with your GP or a specialist in obesity medicine
Not every GLP-1 on the market qualifies, and even within covered medications, only certain forms are included
The forest plot from this meta-analysis is striking
And hopefully the World Health Organization and their declaration is one more united voice, a global voice to get these medications recognized, covered and more readily accessible to those who need them. In a statement to CBC News, P.E.I.'s Department of Health and Wellness said GLP-1 drugs are not covered for weight loss under the province's drug programs
